Literature DB >> 32890757

Real-life experience of an allergy and clinical immunology department in a Portuguese reference COVID-19 hospital.

Leonor Carneiro-Leão1, Luís Amaral2, Alice Coimbra2, José Luís Plácido2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32890757      PMCID: PMC7467073          DOI: 10.1016/j.jaip.2020.08.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
To the Editor: We read with great interest the article by Shaker et al, which suggests a COVID-19 pandemic contingency strategy for Allergy and Immunology (AI) Clinics. Although this guidance is invaluable, in Portugal, the first cases were reported, national state of emergency was declared, and lockdown measures were imposed in March. Such events had a tremendous impact on our AI Department, which is based at an academic hospital and the COVID-19 reference for northern Portugal, the initial national epidemic's epicenter. By sharing our real-life experience during the first 8 weeks of COVID-19 (Table I ), we now hope to complement available guidance, empowering others on strategies for a similar crisis.
Table I

Summary of decisions and production during lockdown and resume of regular activities

ActivityDecision during lockdownn performed/n canceled
Medical appointments
 First visitsCase-by-case decision according to apparent severity but primarily canceled219/365
 Subsequent visitsMaintained. Conversion to phone consultation whenever possible1881§/13
Allergen immunotherapy
 SCIT initiationSuspended0/29
 SCIT maintenanceSuspended; patients were encouraged to maintain regular schedule at their primary care units17/604
 VIT initiationSuspended
 VIT maintenancePredominantly maintained after risk-benefit assessment with patients87/9
Food allergy
 Skin prick-prick testsSuspended0/28
 Food challengesSuspended0/62
 Oral tolerance inductionSuspended0/2
Drug allergy
 Drug skin tests/challengesSuspended0/188
 Rapid drug desensitizationMaintained for antineoplastic drugs16/16
Other procedures
 Lung function testsSuspended0/1040
 Inhalants skin prick testsSuspended0/530
Biological drugsMaintained; conversion to self-administration whenever possible29/46
Urgent care
 Urgent consultationRestricted to mucocutaneous symptoms
 Inpatient consultationsMaintained with PPE
 ER consultationsMaintained with PPE
Medical staff
 Social distancingConverted all staff meetings and intermediate communications into digital meetings via phone calls, WhatsApp, or e-mailCommunication with patients via phone calls, WhatsApp, or e-mailElectronic prescriptions
 Participation in COVID-19 activitiesVoluntary participation: monitoring patients under homecare as part of a broader multispecialty team (that performed around 11,000 consults), COVID-19 dedicated ward, and ED shifts
Scientific activity
 ResearchSuspended and/or redirected to COVID-19
 Continuous educationIn-person meetings suspended. Participation in digital meetings encouraged
 Training programsGlobally suspended

ED, Emergency department; ER, emergency room; PPE, personal protective equipment; SCIT, subcutaneous immunotherapy; VIT, venom immunotherapy.

Includes spirometry with and without bronchodilation, impulse oscillometry, methacholine challenge test, fractional exhaled nitric oxide.

Includes data from March 16 to May 11.

In-person appointments: 124 (57%).

In-person appointments: 43 (2.3%).

Adhered to self-administration program/patients under biological therapy.

Summary of decisions and production during lockdown and resume of regular activities ED, Emergency department; ER, emergency room; PPE, personal protective equipment; SCIT, subcutaneous immunotherapy; VIT, venom immunotherapy. Includes spirometry with and without bronchodilation, impulse oscillometry, methacholine challenge test, fractional exhaled nitric oxide. Includes data from March 16 to May 11. In-person appointments: 124 (57%). In-person appointments: 43 (2.3%). Adhered to self-administration program/patients under biological therapy. Nonurgent activity was suspended, and outpatient appointments were mainly converted to phone consultations, relying on remote access to electronic health records, as well as an online prescribing system that allows prescription fulfillment using e-mail/SMS. We restricted nonscheduled care to urticaria and hereditary angioedema exacerbations. Respiratory complaints were redirected to COVID-19 dedicated emergency department. A new e-mail box was created to answer patient requests and concerns, which were mainly related to heightened risk of infection, treatment safety of nasal/inhaled steroids, and prescription renewal. Telework was authorized for medical staff with high-risk comorbidities. Others volunteered to participate in COVID-19 activities, on top of AI activity. The Infectious Diseases Department devised a homecare program for nonsevere cases to reduce admissions. Physicians would call to communicate a positive SARS-CoV-2 result and educate on isolation measures, with follow-up evaluations at every 24-72 hours, according to patient condition. Other responsibilities were to identify patients in need of in-hospital evaluations and psychological or social support and to initiate recovery protocol. The experience at the outpatient clinic and specific training in respiratory diseases made allergists particularly qualified to monitor patients on homecare, which soon became our focus. Allergen immunotherapy initiations were postponed, and sublingual treatments (inhalant, latex, or Pru p 3) kept at home. Transfer of inhalant immunotherapy injections to primary care units was encouraged. Maintenance venom immunotherapy (VIT) was secured, considering its lifesaving potential. VIT ultra-rush initiations, drug, and food challenges, as well as updosing of oral tolerance inductions, were postponed, averting prolonged in-hospital stay and allergic reactions. Antineoplastic desensitizations were warranted as essential care. Implementation of a self-injection program for omalizumab, benralizumab, and mepolizumab was accelerated. We switched to prefilled syringes/autoinjectors, designed self-administration training protocols and information leaflets, and encouraged all patients to enter the program. Training programs were suspended. Residents were highly involved in the COVID-19 efforts and un-postponed clinical activity. Participation in digital congresses was safeguarded. The uncertainties on how to prioritize service shutdown and patient care and the lack of guidelines were very real and led us to heavily rely on creativity, open-mindedness, and shared decision-making. Despite its dire effects, , , COVID-19 created an opportunity to expedite projects and rethink the role of digital tools, , which proved to be a powerful resource, enabling the safe delivery of quality care. The intense participation in COVID-19 offered a sense of usefulness and companionship during uncertain times. Those were the ultimate silver linings of this crisis.
  2 in total

1.  COVID-19 pandemic and allergen immunotherapy-an EAACI survey.

Authors:  Oliver Pfaar; Ioana Agache; Matteo Bonini; Helen Annaruth Brough; Tomás Chivato; Stefano R Del Giacco; Radoslaw Gawlik; Aslı Gelincik; Karin Hoffmann-Sommergruber; Marek Jutel; Ludger Klimek; Edward F Knol; Antti Lauerma; Markus Ollert; Liam O'Mahony; Charlotte G Mortz; Oscar Palomares; Carmen Riggioni; Jürgen Schwarze; Isabel Skypala; María José Torres; Eva Untersmayr; Jolanta Walusiak-Skorupa; Adam Chaker; Mattia Giovannini; Enrico Heffler; Erika Jensen-Jarolim; Cristina Quecchia; Mónica Sandoval-Ruballos; Umit Sahiner; Vesna Tomić Spirić; Montserrat Alvaro-Lozano
Journal:  Allergy       Date:  2021-08-25       Impact factor: 14.710

2.  Allergic patients during the COVID-19 pandemic-Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey.

Authors:  Montserrat Alvaro-Lozano; Mónica Sandoval-Ruballos; Mattia Giovannini; Erika Jensen-Jarolim; Umit Sahiner; Vesna Tomic Spiric; Cristina Quecchia; Adam Chaker; Enrico Heffler; Ludger Klimek; Helen Brough; Gunter Sturm; Eva Untersmayr; Mateo Bonini; Oliver Pfaar
Journal:  Clin Transl Allergy       Date:  2022-01-17       Impact factor: 5.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.